ChemicalBook
Chinese english Germany Japanese Korea

Anidulafungin Produkt Beschreibung

Anidulafungin Struktur
166663-25-8
CAS-Nr.
166663-25-8
Englisch Name:
Anidulafungin
Synonyma:
Eraxis;Ecalta;LY 303366;nidulafungin;Anidulafungin;LY 303366, Eraxis;Anidulafungin-d11;Anidulafungin(LY303366);Echinocandin B, 1-(4R,5R)-4,5-dihydroxy-N2-4-(pentyloxy)1,1:4,1-terphenyl-4-ylcarbonyl-L-ornithine-;1-[(4R,5R)-4,5-dihydroxy-N2-[[4''-(pentyloxy)[1,1'',1''-terphenyl]-4-yl]carbonyl]-L-ornithine]-echinocandin B
CBNumber:
CB71120054
Summenformel:
C58H73N7O17
Molgewicht:
1140.25
MOL-Datei:
166663-25-8.mol

Anidulafungin Eigenschaften

Sicherheit

Anidulafungin Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Anidulafungin, a semi-synthetic derivative of echinocandin B, has been developed and launched as an intravenous treatment for serious fungal infections, such as candidemia, Candida-derived peritonitis, intra-abdominal abscesses, and esophageal candidiasis. As a non-competitive inhibitor of 1,3-b-D-glucan synthase, which is responsible for the formation of glucan polymers, anidulafungin interferes with the cell wall synthesis of most pathogenic fungi. This mode of action is characteristic of the echinocandin class of antifungals. While the first member of this class, cilofungin, was withdrawn due to toxicity associated with the formulation vehicle, anidulafungin follows the successful introduction of caspofungin and micafungin. Compared to the other echinocandins, anidulafungin appears to be more potent (MIC90 ofr0.25 mg/mL for C.albicans, 0.5 mg/mL for C.glabrata, 1 mg/mL for C. krusel and C.tropicalis, 2mg/mL for C.lusitaniae, and 2 mg/mL for Aspergillus spp) and is devoid of significant drug interactions since it is neither an inhibitor nor substrate of the cytochrome P450 isoenzymes. The emergence of the echinocandins circumvents the concern regarding the rising resistance to the azole and amphotericin B antifungals; no cross-resistance is expected because the echinocandins work at the cell wall rather than the cell membrane.

Originator

Eli Lilly (US)

Verwenden

Anidulafungin is a semi-synthetic cyclic lipopeptide belonging to the echinocandin class that was reported in 1995 and commercially developed by Eli Lilly. Anidulafungin inhibits the synthesis of β-(1,3)-D-glucan, an essential component of the cell wall of susceptible fungi and is extensively referenced in the literature with over 400 citations.

Verwenden

nucleoside reverse transcriptase inhibitor (NRTI) for HIV treatment in adults

Definition

ChEBI: A semisynthetic echinocandin anti-fungal drug. It is active against Aspergillus and Candida species and is used for the treatment of invasive candidiasis.

Trademarks

Eraxis (Vicuron).

Antimicrobial activity

It is active against Aspergillus spp., Candida spp. and the cyst stage of Pneumocystis jirovecii. Resistance has not yet been reported.

Pharmazeutische Anwendungen

A semisynthetic lipopeptide derived from a fermentation product of Aspergillus nidulans. Formulated for intravenous infusion.

Pharmakokinetik

Cmax 100 mg 1-h infusion: c. 9 mg/L end infusion
Plasma half-life: 18–27 h
Volume of distribution: 0.6 L/kg
Plasma protein binding: 84%
Blood concentrations increase in proportion to dosage. The steady state is achieved on the first day after a loading dose (twice the daily maintenance dose).
Distribution
Levels in the CSF are negligible.
Metabolism and excretion
Unlike caspofungin and micafungin, anidulafungin is not metabolized by the liver, but undergoes slow non-enzymatic degradation in the blood to a peptide breakdown product which is enzymatically degraded and excreted in the feces and bile. About 30% of a dose is eliminated in the feces, of which less than 10% is unchanged drug. Less than 1% of a dose is excreted in the urine. No dosage adjustment is required in patients with hepatic or renal impairment. Anidulafungin is not cleared by hemodialysis.

Clinical Use

Candidemia and certain invasive forms of candidosis
Esophageal candidosis

Nebenwirkungen

Occasional histamine-mediated infusion-related reactions, injection site reactions and transient abnormalities of liver enzymes have been reported.

Anidulafungin Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Anidulafungin Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 150)Lieferanten
Firmenname Telefon Fax E-Mail Land Produktkatalog Edge Rate
Henan DaKen Chemical CO.,LTD.
+86-371-55531817
info@dakenchem.com CHINA 21756 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 20672 55
Shanghai Yingrui Biopharma Co., Ltd.
+86-21-33585366 E-mail:sales03@shyrchem.com
+86-21-34979012 sales03@shyrchem.com CHINA 661 60
ATK CHEMICAL COMPANY LIMITED
+86 21 5161 9050/ 5187 7795
+86 21 5161 9052/ 5187 7796 ivan@atkchemical.com CHINA 24192 60
Lianyungang happen teng technology co., LTD
15950718863
wang666xt@163.com CHINA 296 58
career henan chemical co
+86-371-86658258
sales@coreychem.com CHINA 27142 58
TianYuan Pharmaceutical CO.,LTD
+86-755-23284190 13684996853
+86-755-23284190 sales@tianpharm.com CHINA 306 58
Chemwill Asia Co.,Ltd.
86-21-51086038
86-21-51861608 chemwill_asia@126.com;sales@chemwill.com;chemwill@hotmail.com;chemwill@gmail.com CHINA 23962 58
QUALITY CONTROL CHEMICALS INC.
(323) 306-3136
(626) 453-0409 orders@qcchemical.com United States 8407 58
Xiamen AmoyChem Co., Ltd
+86 592-605 1114
sales@amoychem.com CHINA 6370 58

166663-25-8()Verwandte Suche:


  • Anidulafungin
  • Echinocandin B, 1-(4R,5R)-4,5-dihydroxy-N2-4-(pentyloxy)1,1:4,1-terphenyl-4-ylcarbonyl-L-ornithine-
  • Anidulafungin(LY303366)
  • Ecalta
  • Eraxis
  • LY 303366
  • LY 303366, Eraxis
  • 1-[(4R,5R)-4,5-dihydroxy-N2-[[4''-(pentyloxy)[1,1'',1''-terphenyl]-4-yl]carbonyl]-L-ornithine]-echinocandin B
  • nidulafungin
  • Anidulafungin-d11
  • 166663-25-8
  • 66663-25-8
  • C58H73N7O17
  • Antifungals
  • API
  • Inhibitors
Copyright 2019 © ChemicalBook. All rights reserved